Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
| Quarter | Letter Date | Fund Name | QTD | YTD | Tickers | Themes | Quick Take |
|---|---|---|---|---|---|---|---|
Buyside Digest is not affiliated with, and does not endorse, Fundsmith Equity Fund. This analysis is provided for institutional research purposes only and is not investment advice.
"The Fundsmith Equity Fund fell 1.9% in the first half of 2025, primarily dragged down by corporate governance issues at Danish medical holdings Novo Nordisk and Coloplast, as well as currency headwinds from a weaker US Dollar."
In his semi-annual letter for the first half of 2025, Terry Smith of Fundsmith LLP reports that the Fundsmith Equity Fund fell by 1.9% in GBP terms, underperforming the MSCI World Index (£ net), which rose by 0.1%. Despite this short-term underperformance, the fund's annualized return since inception remains robust at 14.1% compared to 11.6% for equities. The primary positive contributors to performance during the half-year were Philip Morris (+1.8%), Meta Platforms (+1.4%), Microsoft (+0.8%), IDEXX (+0.8%), and L'Oréal (+0.7%). Conversely, the largest detractors were Novo Nordisk (-1.7%), LVMH (-1.1%), Waters (-0.6%), Alphabet (-0.5%), and Coloplast (-0.5%). Smith highlights specific corporate governance issues, noting that both Novo Nordisk and Coloplast have fired their CEOs following operational and regulatory failures. Furthermore, currency headwinds significantly impacted returns; while the GBP-denominated fund fell 1.9%, the US Dollar-denominated version was up 6.3% due to a 9% depreciation in the US Dollar relative to the Pound. Over the period, the fund initiated new stakes in Zoetis, Intuit, and EssilorLuxottica, while completely exiting its positions in PepsiCo and Brown-Forman, resulting in a portfolio turnover of 9.2%.
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Market Conviction
High-conviction positioning: The Fundsmith Equity Fund fell 1.9% in the first half of 2025, primarily dragged down by corporate governance issues at Danish medical holdings Novo Nordisk and Coloplast, as well ...
Growth Outlook
Market outlook remains moderate conviction: The Fundsmith Equity Fund fell 1.9% in the first half of 2025, primarily dragged down by corporate governance issues at Danish medical holdings Novo Nordisk and Coloplast, as well ...
Risk Appetite
Risk appetite posture is moderate conviction: The Fundsmith Equity Fund fell 1.9% in the first half of 2025, primarily dragged down by corporate governance issues at Danish medical holdings Novo Nordisk and Coloplast, as well ...
Capital Deployment
Manager actively deployed capital into high-conviction opportunities. The Fundsmith Equity Fund fell 1.9% in the first half of 2025, primarily dragged down by corporate governance issues at Danish medical holdings Novo Nordisk and Coloplast, as well ...
Forward Guidance
Forward guidance signal: The Fundsmith Equity Fund fell 1.9% in the first half of 2025, primarily dragged down by corporate governance issues at Danish medical holdings Novo Nordisk and Coloplast, as well ...
Language Signal
Tone analysis indicates moderate conviction language: The Fundsmith Equity Fund fell 1.9% in the first half of 2025, primarily dragged down by corporate governance issues at Danish medical holdings Novo Nordisk and Coloplast, as well ...
Perceived Risk
Perceived risk level is evaluated as moderate conviction. The Fundsmith Equity Fund fell 1.9% in the first half of 2025, primarily dragged down by corporate governance issues at Danish medical holdings Novo Nordisk and Coloplast, as well ...
Opportunity Density
Opportunity density index indicates above average conviction actionable entry points. The Fundsmith Equity Fund fell 1.9% in the first half of 2025, primarily dragged down by corporate governance issues at Danish medical holdings Novo Nordisk and Coloplast, as well ...
Time Horizon
Investment time horizon reflects a high conviction orientation. The Fundsmith Equity Fund fell 1.9% in the first half of 2025, primarily dragged down by corporate governance issues at Danish medical holdings Novo Nordisk and Coloplast, as well ...
